Sugi Predict

Sugi Predict / Compounds / SCHEMBL30891267

SCHEMBL30891267

SCHEMBL30891267

C[C@@H]1O[C@@H](OCCNC(=O)CN(CC(=O)NCCO[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](CCCCNC(=O)CN(CC(=O)NCCCCCNC(=O)CN(CC(=O)O)CC(=O)NCCCCCC(=O)OCc2ccccc2)CC(=O)NCCO[C@H]2O[C@H](C)[C@H](O)[C@H](O)[C@H]2O)C(=O)NCCO[C@@H]2O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.42

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ EPOR P19235 9/20 0.42
▸ SIRT2 Q8IXJ6 3/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ FOLH1 Q04609 2/20 0.36
▸ SELP P16109 2/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ SIRT1 Q96EB6 1/20 0.35
▸ SIRT3 Q9NTG7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891349 1.00 EPOR (0.42) EPORSIRT2MEN1ALDH1A1HPGD
SCHEMBL29454845 0.94 EPOR (0.45) EPORSIRT2MEN1ALDH1A1HPGD
SCHEMBL23497304 0.93 FOLH1 (0.42) EPORSIRT2FOLH1
SCHEMBL29880862 0.93 FOLH1 (0.42) EPORSIRT2FOLH1
SCHEMBL23575125 0.91 EPHX2 (0.41) SIRT2MEN1ALDH1A1HPGDKMT2A
SCHEMBL30891468 0.91 EPOR (0.42) EPORSIRT2MEN1ALDH1A1HPGD
SCHEMBL29879947 0.91 SIRT2 (0.45) EPORSIRT2FOLH1SIRT1SIRT3
SCHEMBL30891453 0.91 SIRT2 (0.45) EPORSIRT2FOLH1SIRT1SIRT3
SCHEMBL30891352 0.91 FOLH1 (0.42) EPORSIRT2FOLH1
SCHEMBL16620335 0.90 EPHX2 (0.40) SIRT2MEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 — — US disclosed
EP-4615487-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2025-09-17 — — EP disclosed
WO-2024102633-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R EPOR 88/4885SIRT2 836/4885MEN1 1276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback